glp 1 kidney disease GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Glucagon-like peptide-1 receptor agonists in

Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications primarily prescribed for type 2 diabetes management and, in some formulations, for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

The cost is also much less expensive than the injectable, potentially making the therapy accessible to more people who would not qualify for insurance to cover it

Understanding when lifestyle interventions alone are insufficient is essential for appropriate patient care and preventing disease progression

In 2019, Alhashem and colleagues described successful treatment of postoperative NAION with HBO T (both articles published in Undersea and Hyperbaric Medicine -UHM)

By simplifying the process, telehealth makes medically supervised weight management more accessible

Patients felt better, and their cardiovascular risk profile improved a lot